Clinical trials: Oesophageal Cancer Nos
Esophageal Cancer
Combination Chemotherapy and Interferon Alfa Followed by Surgery and/or Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells.
- Trial name
- NCT00004897
- Testing
- recombinant interferon alfa, cisplatin, fluorouracil
- Where
- United States
- Sponsor
- Northwestern University
Bladder Cancer, Cervical Cancer
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
RATIONALE: Stop-smoking plans, including counseling and nicotine replacement therapy, may help smokers quit smoking. It is not yet known whether counseling and the nicotine lozenge is more effective than counseling and the…
- Conditions
- Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00365508
- Testing
- nicotine lozenge, nicotine patch
- Where
- 10 sites in United States
- Volunteers
- 642 people
- Sponsor
- Fox Chase Cancer Center
Hypoxia, Esophageal Cancer
COMBO Endoscopy Oropharyngeal Airway in Sedated Gastrointestinal Endoscopy for Obese Patients
Hypoxia represents the prevailing adverse occurrence during the sedation of patients undergoing gastrointestinal endoscopy with propofol. This is particularly true for obese patients, who have a higher incidence of hypoxia.
- Conditions
- Hypoxia, Esophageal Cancer, Colon Cancer, Gastric Cancer
- Trial name
- NCT06804876
- Testing
- the COMBO Endoscopy Oropharyngeal Airway
- Where
- China
- Volunteers
- 107 people
- Sponsor
- Zhejiang University
Esophagus Cancer
Neoadjuvant Chemotherapy Compared With Surgery for Esophageal Carcinoma
Most ESCC received NAC in China without supportive evidence from local RCTs. The negative conclusion about NAC originated from Western countries in the 1990s.
- Trial name
- NCT05569668
- Testing
- Paclitaxel- and platinum-based chemotherapy
- Where
- China
- Volunteers
- 826 people
- Sponsor
- Henan Cancer Hospital
Gastric Cancer, Gastroesophageal Junction Cancer
Human Epidermal Growth Factor Receptor 2 (HER-2) Status in Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma
The primary objective is to evaluate the concordance between human epidermal growth factor receptor 2 (HER2) status determined by the participating laboratory and by the centralized laboratory.
- Trial name
- NCT02731313
- Testing
- Trastuzumab
- Where
- 19 sites in France
- Volunteers
- 420 people
- Sponsor
- Hoffmann-La Roche
Esophageal Squamous Cell Carcinoma
Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.
This is a phase II, open label, two-centered study for evaluation of the addition of nivolumab and cetuximab after chemoradiation as a neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma patients.
- Trial name
- NCT04229459
- Testing
- Cisplatin, 5-FU, Radiation therapy
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Baruch Brenner
Esophageal Cancer, Neoantigen
Computational Prediction and Experimental Validation of Esophageal Cancer Associated Neoantigens
This study is to develop computational pipelines and experimental validation assays for improving the identification of neoantigens from patients with esophageal cancer.
- Trial name
- NCT05498168
- Testing
- ratio of predicted neoantigens
- Where
- Vietnam
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University Medical Center Ho Chi Minh City (UMC)
Esophageal Cancer, GastroEsophageal Cancer
Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA
The purpose of this study is to collect real-world data to describe the effectiveness and tolerability of first line (1L) zanidatamab-containing therapies and describe the subsequent lines of treatment in participants with…
- Conditions
- Esophageal Cancer, GastroEsophageal Cancer, Gastroesophageal-junction Cancer, HER2-positive Gastric Cancer
- Trial name
- ZOLA (NCT07780968)
- Testing
- Zanidatamab
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Jazz Pharmaceuticals
Esophageal Diseases, Esophagus SCC
Cytosponge™ Feasibility Study in Tanzania
A Tanzanian pilot study to test the feasibility of using the Cytosponge™ device - a less-invasive endoscopy alternative - for research on esophageal squamous cell carcinoma in African settings.
- Trial name
- CytoSCCAPE (NCT04090554)
- Testing
- Cytosponge™
- Where
- Tanzania
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- International Agency for Research on Cancer
Esophageal Cancer
Is Screening for Esophageal Pathology in Asymptomatic Patients Post-Treatment for Head and Neck Cancer Beneficial?
The purpose of this study is to evaluate the prevalence of esophageal pathology in asymptomatic patients with a history of head and neck cancer.
- Trial name
- NCT00583934
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of California, Davis
Esophageal Cancer
Treatment Outcomes of Esophageal Cancer
This study will be a carried out through a prospective observational cohort design in conjunction with researchers in the African Esophageal Cancer Consortium (AfrECC).
- Trial name
- NCT05177393
- Testing
- Assessment of patient-reported outcomes (PROs)
- Where
- 6 sites in Kenya, Malawi and 1 more
- Volunteers
- 2,476 people
- Sponsor
- University of California, San Francisco
Carcinoma, Hepatocellular, Gastric Adenocarcinoma
A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers
This study is a prospective, open label, multi-centre phase 2 trial which assesses the efficacy and safety of standard dosing compared to extended dosing interval of nivolumab, atezolizumab or pembrolizumab in…
- Conditions
- Carcinoma, Hepatocellular, Gastric Adenocarcinoma, GastroEsophageal Cancer, Oesophageal Cancer
- Trial name
- VALUE-CHECK (NCT06422403)
- Testing
- Extended Dosing Interval - A, Extended Dosing Interval - B, Extended Dosing Interval - C
- Where
- Singapore
- Volunteers
- 360 people
- Sponsor
- National University Hospital, Singapore
Esophageal Cancer
Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00702884
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Tony Bekaii-Saab
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma
- Trial name
- NCT05334069
- Testing
- Questionnaire Administration, Biospecimen Collection
- Where
- 751 sites in United States
- Volunteers
- 2,900 people, healthy volunteers welcome
- Sponsor
- Alliance for Clinical Trials in Oncology
Esophagus Cancer
Prediction of Lymphatic Metastasis in Esophageal Cancer by CT Radiomics
This study proposes to establish a CT radiomics-based prediction model for identifying metastasis lymph nodes in esophageal cancer.
- Trial name
- NCT03237130
- Testing
- preoperative enhanced chest CT examination
- Where
- China
- Volunteers
- 133 people
- Sponsor
- Peking University Cancer Hospital & Institute
Esophageal Cancer
PD-1 Inhibitor INCMGA00012 as Consolidation Therapy After Definitive Concurrent Chemoradiotherapy
This study is a randomized, multi-center, open-label, phase II study of a PD-1 inhibitor (INCMGA00012) versus observation as consolidation therapy after definitive concurrent chemoradiotherapy in patients with locally advanced…
- Trial name
- RHAPSODY (NCT04494009)
- Testing
- INCMGA00012
- Where
- South Korea
- Volunteers
- 110 people
- Sponsor
- Asan Medical Center
Esophageal Cancer
Temporal Variation in Exhaled Volatile Organic Compounds in Esophageal Cancer Patients
The purpose of this study is to investigate whether exhaled breath can be used to detect and monitor esophageal cancer.
- Trial name
- NCT06453993
- Testing
- Exhaled VOC breath test
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 46 people
- Sponsor
- Benaroya Research Institute
Locally Advanced Esophageal Squamous Cell Carcinoma, Sintilimab
Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma
At present, concurrent chemoradiotherapy (cCRT) with platin-based dual-drug regimen is the standard treatment for inoperable, locally advanced esophageal cancer in patients with a good performance status.
- Conditions
- Locally Advanced Esophageal Squamous Cell Carcinoma, Sintilimab, Radiotherapy, Concurrent Chemoradiotherapy
- Trial name
- NCT06342167
- Testing
- Radiotherapy, Programmed Cell Death Protein 1 Inhibitor, Immunonutrition support
- Where
- 10 sites in China
- Volunteers
- 57 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma
Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer
This phase II trial studies the side effects of epacadostat and pembrolizumab and to see how well they work before surgery in treating participants with stage II-III esophageal or gastroesophageal cancer.
- Conditions
- Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT03592407
- Testing
- Epacadostat, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 3 sites in United States
- Sponsor
- City of Hope Medical Center
Esophageal Carcinoma, Gastroesophageal Junction Carcinoma
A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer
The purpose of this study is to describe the effectiveness and use of nivolumab after surgery in participants with early stage (Stage II/III) Esophageal Cancer/Gastroesophageal Junction Cancer (EC/GEJC).
- Trial name
- PROSPECT-ESO (NCT05780736)
- Where
- 24 sites in United States, Germany
- Volunteers
- 33 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.